- Report
- August 2024
- 101 Pages
Global
From €3500EUR$4,136USD£3,134GBP
- Report
- July 2024
- 98 Pages
Global
From €3500EUR$4,136USD£3,134GBP
- Report
- January 2024
- 81 Pages
Global
From €3500EUR$4,136USD£3,134GBP
- Report
- August 2022
- 78 Pages
Global
From €3500EUR$4,136USD£3,134GBP
- Report
- August 2023
- 112 Pages
Global
From €3500EUR$4,136USD£3,134GBP
- Report
- February 2023
- 248 Pages
Global
From €3236EUR$3,570USD£2,800GBP
- Book
- July 2022
- 880 Pages
- Book
- January 2010
- 200 Pages
The Ventricular Assist Device (VAD) market is a subset of the Cardiovascular Devices market. VADs are mechanical pumps that are implanted in the body to help the heart pump blood. They are used to treat heart failure, bridge patients to heart transplantation, and provide long-term support for patients with end-stage heart failure. VADs are typically used in patients who are not eligible for heart transplantation or who are waiting for a donor heart.
VADs are classified into two main categories: left ventricular assist devices (LVADs) and right ventricular assist devices (RVADs). LVADs are used to support the left ventricle, while RVADs are used to support the right ventricle. Both types of VADs are designed to improve the quality of life of patients with heart failure.
Some companies in the VAD market include Abiomed, Medtronic, Thoratec, and SynCardia. Show Less Read more